XML 23 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Cash Flows
 12 Months Ended
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Cash flows from operating activities:      
Net loss $ (29,102,837) $ (36,140,133) $ (66,083,532)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 1,048,431 626,554 328,752
Amortization of intangible assets 870,199 942,719 1,770,537
Change in value of common stock warrants (177,561) (348,143) 45,632,669
Stock-based compensation 6,186,848 5,428,946 1,868,345
Issuance of shares in connection with reverse stock split 0 57,187 0
Amortization of premiums on investments 348,566 54,534 (484)
Deferred taxes 14,166 27,537 32,274
Deferred rent 383,584 762,616 410,187
Transaction costs associated with issuance of warrants 0 0 315,970
Loss on short-term investments 424,275 33,990 38,950
Loss on disposal of fixed assets 7,899 2,959 1,822
(Gain) Loss on investment in affiliated entity (2,600,467) (2,676,224) 1,038,745
Gain on sale of intangible assets (1,000,000) 0 (2,000,000)
Income tax benefit from other unrealized gains on securities (2,097,766) 0 0
Changes in operating assets and liabilities:      
Accounts receivable (4,528,852) 497,356 (2,434,896)
Prepaid expenses and other current assets (119,284) (160,540) (229,705)
Prepaid expenses and other current assets from affiliated entity 771,723 674,975 (1,401,258)
Restricted cash 0 100,762 (352)
Other assets (196,265) (72,493) 26,793
Accounts payable and accrued expenses 6,456,581 925,820 2,123,761
Accrued clinical trial expenses 593,051 561,252 40,284
Accounts payable and accrued expenses due to affiliated entity 136,640 (493,848) 334,980
Deferred revenue 10,191,840 (260,719) 3,179,721
Deferred revenue from affiliated entity (49,672) (368,751) (375,000)
Net cash used in operating activities (12,438,901) (29,823,644) (15,381,437)
Cash flows from investing activities:      
Purchases of investments (63,526,830) (47,185,945) (15,399,495)
Maturities of investments 10,484,267 12,753,719 4,339,577
Purchases of capital assets (2,781,544) (1,379,980) (176,925)
Proceeds from sale of intangible assets 1,000,000 0 2,000,000
Net cash used in investing activities (54,824,107) (35,812,206) (9,236,843)
Cash flows from financing activities:      
Proceeds from issuance of common stock and warrants, net of issuance costs 81,902,363 59,209,182 32,883,705
Proceeds from stock option and warrant exercises 2,598,915 13,252,543 19,808,232
Other financing activities (149,559) 0 0
Net cash provided by financing activities 84,351,719 72,461,725 52,691,937
Effect of exchange rate changes on cash and cash equivalents 0 (1,689) 118
Increase in cash and cash equivalents 17,088,711 6,824,186 28,073,775
Cash and cash equivalents, beginning of period 40,543,982 33,719,796 5,646,021
Cash and cash equivalents, end of period 57,632,693 40,543,982 33,719,796
Supplemental disclosure of non-cash activities      
Amounts accrued for purchases of property and equipment 225,148 12,842 139,173
Lease incentive recorded as fixed assets and deferred rent $ 773,000 $ 933,000 $ 2,538,000